Skip to main content
Celemics, Inc. logo

Celemics, Inc. — Investor Relations & Filings

Ticker · 331920 ISIN · KR7331920009 KO Manufacturing
Open in API
Filings indexed 187 across all filing types
Latest filing 2026-05-21 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 331920

About Celemics, Inc.

https://www.celemics.com/

Celemics, Inc. is a biotechnology company that develops and provides Next-Generation Sequencing (NGS) solutions for research and clinical applications. The company specializes in hybridization-based target enrichment technology, offering a comprehensive portfolio of products and services. This includes ready-to-use and customized NGS panels, whole exome sequencing kits, library preparation kits, modular accessories, and bioinformatics analysis services. Celemics' solutions support a wide range of fields, including oncology (somatic cancer, liquid biopsy), inherited diseases, pathogen analysis, pharmacogenomics, and immune repertoire profiling. A key focus is the development of end-to-end customized target enrichment panels, providing support from assay design and optimization to complete bioinformatics analysis. The company's proprietary technologies in probe design and molecular barcoding enable efficient analysis of diverse and challenging sample types.

Recent filings

Filing Released Lang Actions
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 93% confidence The document is a ‘주요사항보고서’ (material event report) filed with the Korean Financial Supervisory Service/Exchange announcing and detailing a decision on a 유상증자 (paid-in capital increase). It provides extensive specifics on the share issuance method, allotment, use of proceeds, timeline, and related board resolutions. This aligns with the ‘Share Issue/Capital Change’ category (SHA).
2026-05-21 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is titled “분기보고서” (Quarterly Report) covering the period 2026-01-01 to 2026-03-31 for 주식회사 셀레믹스. It contains detailed financial statements, business overview, sales, cost tables, market risk discussions, R&D activities, and other substantive interim period financial disclosures. This aligns exactly with the definition of an Interim/Quarterly Report. Q1 2026
2026-05-15 Korean
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 89% confidence The document is an amended '주요사항보고서(유상증자결정)' (Material Event Report – decision on paid‐in capital increase), detailing terms of a new share issuance, correction of the new shares listing date, issuance price, allocation, and related details. This is a direct announcement of a share issue/capital change, not merely a notice of publication or regulatory attestation. Therefore it falls under Share Issue/Capital Change (SHA).
2026-05-12 Korean
주식등의대량보유상황보고서(약식)
Regulatory Filings
2026-05-08 Korean
주식등의대량보유상황보고서(일반)
Regulatory Filings
2026-05-07 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Regulatory Filings
2026-05-07 Korean

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.